No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
RAY Co., Ltd. specializes in delivering x-ray diagnostic tools for the dental sector. Their comprehensive product lineup features the RAYSACN Series, RAYios, RAYFace, RAYDENT Microscan, and the RIO Series, in addition to RAYDENT designer and tray, RAYSmiler, RAYDENT Studio, and the RAYDENT Mill 4X and 5X. They also supply related consumables. Founded in 2004, the company's main operations are based in Seongnam-si, South Korea.
www.raymedical.comNo one on the platform currently holds 228670.KQ.
No tracked institution reports a position in 228670.KQ as of their last filing.
No one on the platform has traded 228670.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -5.9% | — | — | — | ||
| Rev. Growth % | 39.3% | 15.0% | ||||
| Profit Margin % | 2.8% | -13.6% | ||||
| Free Cash Flow Margin % | 10.1% | -11.2% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $130.2B | +17.8% | $479.00 | $479.00–$479.00 | — | 1 |
| 2027 | $151.6B | +16.4% | $707.00 | $707.00–$707.00 | — | 1 |
| 2028 | $173.1B | +14.2% | $829.75 | $829.75–$829.75 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-12 | $-159.00 | $-628.27 | -295.1% |
| 2025-11-12 | $442.00 | $886.00 | +100.5% |
| 2025-08-14 | $453.00 | $-218.69 | -148.3% |
| -2.86% |
| $63.2B |
| — |
| 183490.KQEnzychem Lifesciences Corporation | $990.00 | -2.65% | $83.8B | — |
| 253840.KQSugentech Inc. | $4560.00 | -0.87% | $69.7B | — |
Source: Financial Modeling Prep · peers by sector/industry